Epithelial-mesenchymal transition biomarkers in patients with acute exacerbation of COPD are indicative of disease severity, disease progression, and risk of readmission
Int. Journal of Clinical Pharmacology and Therapeutics · 2025
DOI: 10.5414/cp204769 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Int. Journal of Clinical Pharmacology and Therapeutics, 2025. Verfasst von Xiaohua Chou und 6 weiteren Autor:innen. Hauptthemen laut MEDLINE: Pulmonary Disease, Chronic Obstructive, Patient Readmission, Epithelial-Mesenchymal Transition. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Themen: COPD
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Zitieren
APA
Chou, X., Zhang, Q., Li, Y., Qiu, X., Sha, Q., Gu, Y., & Jiang, D. (2025). Epithelial-mesenchymal transition biomarkers in patients with acute exacerbation of COPD are indicative of disease severity, disease progression, and risk of readmission. Int. Journal of Clinical Pharmacology and Therapeutics. https://doi.org/10.5414/cp204769
Vancouver
Chou X, Zhang Q, Li Y, Qiu X, Sha Q, Gu Y, et al. Epithelial-mesenchymal transition biomarkers in patients with acute exacerbation of COPD are indicative of disease severity, disease progression, and risk of readmission. Int. Journal of Clinical Pharmacology and Therapeutics. 2025. doi:10.5414/cp204769
BibTeX
@article{Chou2025,
author = {Chou, Xiaohua and Zhang, Qian and Li, Yuanqin and Qiu, Xinran and Sha, Qian and Gu, Yongli and Jiang, Daoli},
title = {Epithelial-mesenchymal transition biomarkers in patients with acute exacerbation of COPD are indicative of disease severity, disease progression, and risk of readmission},
journal = {Int. Journal of Clinical Pharmacology and Therapeutics},
year = {2025},
doi = {10.5414/cp204769}
}
EUVIMED